EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This phase Ib/II trial studies the side effects and best dose of EMB-01 when given together
with osimertinib in patients with EGFR-mutant non-small cell lung cancer that has spread to
other places in the body (advanced or metastatic) and has progressed on standard treatment.
EMB-01 and osimertinib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth in this type of cancer. EMB-01 in combination with osimertinib may
work better in treating patients with EGFR-mutant advanced non-small cell lung cancer.